Peptide RegisterUK

Home / Tools / Evidence

What is the evidence?

Every compound in the register, grouped by how strong the evidence actually is. Strongest first. This is the single most useful thing to know before reading anything else about a compound.

Human RCT, phase 3

Large randomised controlled trials in people, the standard a regulator needs before approving a medicine. This is the strongest evidence available for anything.

Read the trial, and check the comparator, the duration and who funded it.

Phase 3 reported, no approval

Large human trials exist and have reported, but no regulator has yet completed an assessment. Promising is not the same as approved.

Watch for the regulatory decision rather than the press release.

Phase 3 ongoing

Large human trials are running but not finished. Any figures circulating are from earlier phases or interim looks.

Treat specific percentages with real caution.

Human trials exist and contradict each other

People have been studied and the studies disagree. That usually means any real effect is small enough to be swamped by trial design and chance.

Contradictory is its own answer, and not an encouraging one.

Human trials exist, no approval

Studied in people, never approved. Sometimes the effect was too small, sometimes safety concerns emerged. Either way the programme that would have set a safe dose was not finished.

Ask what the trials found besides the headline effect.

Limited early human studies

Some human work exists but it is small and was never carried through to licensing.

Early human data is a reason to run trials, not a reason to act.

Russian clinical use, limited Western trial data

Decades of real prescribing in one regulatory system, without the controlled trial data Western regulators require. Long use tells you it has not obviously harmed people; it does not establish effect size.

A real critique of Western trial bias exists here. It also does not create missing data.

Cohort studies from one research group. No modern controlled trials.

The positive findings come almost entirely from the group that developed the compound. Independent replication is how science catches error and enthusiasm.

Ask whether anyone else has found the same thing.

Human trials did not support the claims

Tested in people for the purpose it is sold for, and it failed. This is not missing evidence. It is evidence pointing the other way.

The strongest possible reason not to bother.

Animal studies, almost no human data

Effects reported in rats, mice or cells in a dish, with essentially nothing in people. Most compounds that work in animals fail in humans.

Look for the word rat, mouse or in vitro in any source.

Animal studies, no human trials

Animal and laboratory work only. No human trial evidence at all.

Nobody can honestly quote you a benefit or a risk figure.

No human trials

No human clinical studies exist. In several July 2026 FDA reviews, this was the regulator's own finding.

An absence of evidence is not evidence of suppression.

No human trials of the peptide itself

No human studies of this compound. Where controlled human data exists, it used a different, modified molecule, and research on that gets presented as research on this.

Check which molecule a study actually used.

Abandoned in development, no supporting human trials

A real drug candidate that entered human trials and was dropped before finishing. The work that would have established safety and a dose was never completed.

Abandonment is not proof of danger, and not proof of suppression either.

No human trials supporting marketed claims

Early pharmacology may show it does something measurable, such as moving a blood marker. Whether that produces the outcomes it is sold for has not been tested.

Moving a marker is not the same as a benefit.

Human RCT for its licensed indication

Proper trials, for one specific condition in one specific population. That is real evidence, and it is narrow evidence.

Check whether you resemble the people studied.

Human RCT for licensed uses

Proper randomised trials, for the specific conditions it is licensed to treat. Strong evidence, narrowly scoped.

Evidence for treating a deficiency is not evidence for topping up someone normal.

How to use this

The tiers are the point

Almost every argument about these compounds online is really an argument about which tier the evidence sits in, conducted without anyone saying so. Establish the tier first and most of the argument evaporates.

How to read a claim